Patent · US Active

Enhancing coagulation or reducing fibrinolysis

US8697747B2 · kind B2 · utility

4Cited by
1References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 5, 2010
Grant dateApr 15, 2014
Priority date
Expiry dateMar 5, 2030

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P9/12
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Methods for controlling bleeding (e.g., enhancing coagulation and reducing fibrinolysis) in a subject are disclosed. The methods include selecting a subject in need of enhanced coagulation or reduced fibrinolysis, and administering to the subject a carbon monoxide releasing molecule (CORM). Examples of CORMs include tricarbonyldichloro-ruthenium (II) dimer, tricarbonylchloro-(glycinato)ruthenium (II), sodium boranocarbonate, dimanganese decacarbonyl, and iron pentacarbonyl. Further disclosed are compositions and methods for treating a subject in need of a blood product by administering to the subject a composition including a CORM and a blood product (e.g., cryoprecipitate or fresh frozen plasma).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.